表紙
市場調查報告書

血糖值測試紙的全球市場:成長率、趨勢、預測

Global Blood Glucose Test Strips Market - Segmented by Device Type, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 567961
出版日期 內容資訊 英文 116 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血糖值測試紙的全球市場:成長率、趨勢、預測 Global Blood Glucose Test Strips Market - Segmented by Device Type, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年03月01日內容資訊: 英文 116 Pages
簡介

本報告提供全球血糖值測試紙的市場相關分析,產品概要和市場基本結構,主要的推動及阻礙市場的要素,市場規模趨勢預測 (今後6年份),各技術、各流通形態及各地區詳細趨勢,市場競爭環境,主要企業簡介,今後的投資、市場機會預測等調查。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 市場概況
  • 近幾年的市場動向
  • 波特的五力分析

第6章 市場的推動因素與阻礙因素、機會、課題分析

  • 市場的推動要素
  • 市場的阻礙要素
  • 現在的市場機會
  • 主要課題

第7章 全球血糖值測試紙市場明細

  • 各技術
    • 芯吸技術 (芯型技術)
    • 流通管道技術
  • 各流通形態
    • 醫院內
    • 市售 (藥局)

第8章 全球血糖值測試紙市場:各地區

  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (英國,德國,法國,義大利,西班牙等)
  • 亞太地區 (中國,日本,印度,澳洲,韓國等)
  • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
  • 南美 (巴西,阿根廷等)

第9章 競爭環境

  • 企業合併、收購 (M&A)
  • 新產品的銷售
  • 協定,產業合作、聯盟

第10章 主要供應商分析

  • Abbott Laboratories
  • Palmsens
  • Acon Laboratories, Inc,
  • Apex Biotechnology Corporation
  • Ascensia Diabetes Care Holdings Ag
  • B.Braun Melsungen Ag
  • HMD Biomedical
  • Lifescan, Inc.
  • I-Sens, Inc
  • Roche Diagnostics

第11章 市場未來展望

第12章 投資機會分析、展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49395

In 2017, the global blood glucose test strips market was estimated at around USD 11,000 million. The market is expected to register a CAGR of about 6.5% during 2018-2023 (the forecast period). North America, followed by Asia-Pacific, accounts for the largest share in the blood glucose test strips market.

Convenience of CGM over Conventional Monitoring

Continuous glucose monitoring (CGM) provides a frequent and real-time feedback about glucose levels and retrospective 24-hrs glucose profiles. Incorporating CGM in the treatment of type 1 diabetes (T1D) has given potential advantages over conventional self-monitoring of blood glucose (SMBG). The real-time use of CGM results can equip people with T1D and parents of youths with T1D, to respond promptly and address glycemic excursions, minimizing, both, hyperglycemia and hypoglycemia. Retrospective use of CGM profiles can reveal recurring glycemic fluctuations that are not apparent with conventional SMBG, permitting regimen adjustments to stabilize glucose control. As CGM systems have become more widespread, the market for blood glucose test strip is likely to experience growth. Moreover, owing to the rising diabetic population and technological advancements, this market is expected to grow and combat diabetes.

High Cost Per Strip

Diabetes treatment requires constant monitoring of glucose levels. If blood glucose levels are not monitored regularly, it can lead to severe complications. Diabetes management process is an expensive service. At large scale, patients use blood glucose test strips. The retail cost of these strips varies from 50 cents per strip to as high as USD 5 per strip. Since, constant monitoring is necessary for diabetic patients, the cost often becomes a problem. Although various countries, like the United Kingdom, provide reimbursements for prescribed test strips, the majority patients have to pay for them from their pockets. The frequency of monitoring glucose levels depends on the type of diabetes and varies from patient to patient. For type 1 diabetes patients, at least four tests are advised per day. If the patient is using insulin injections, the count can go up to seven tests per day. Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be over USD 180 each month. These expenses add to the already high diabetes management costs and are impeding the market growth.

North America to Dominate the Market Growth

North America accounted for the largest share of 56% of the global market, owing to the availability of healthcare reimbursements and the fastest adoption rate for new medical technologies. Europe is also the leading region in the global blood glucose test strips market. Asia-Pacific is the fastest growing region for blood glucose test strips market and portrays a huge potential for growth in the future, due to the increasing government initiatives to combat diabetes and corporate investments to streamline R&D in diabetes.

Key Developments in the Market

January 2018: Ascensia Diabetes Care announced the expansion of its strategic alliance with Insulet Corporation, a leader in tubeless insulin pump technology, by signing a global commercial agreement. This expansion follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017, to connect its CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) with Insulet's next-generation Omnipod System (Omnipod DASH™).

Major Players: ROCHE DIAGNOSTICS, LIFESCAN, BAYER HEALTHCARE, ABBOTT LABORATORIES, ARKRAY INC., ACON LABORATORIES, APEX BIOTECHNOLOGY CORPORATION, ASCENSIA DIABETES CARE, HMD BIOMEDICAL, B. BRAUN MELSUNGEN AG amongst others.

Reasons to Purchase this Report

Current and future the blood glucose test strips market outlook in the developed and emerging markets

Analyzing various market perspectives, with the help of Porter's five forces analysis

The segment that is expected to dominate the market

The regions that are expected to witness fastest growth during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Product & Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Convenience of CGM Over Conventional Monitoring
    • 6.1.2 Early Detection of Hypo and Hyperglycemic Diabetes
    • 6.1.3 Technological Innovations
    • 6.1.4 Global Rise in the Diabetic Population
  • 6.2 Market Restraints
    • 6.2.1 Less Attractive Reimbursement Coverage
    • 6.2.2 Reimbursement Issues
    • 6.2.3 Patent Expiry Depleted Profit of the Market
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Device Type
    • 7.1.1 Blood Glucose Meter
    • 7.1.2 Blood Glucose Testing Strips
    • 7.1.3 Lancets
    • 7.1.4 Continuous Glucose Monitoring Devices (CGM)
    • 7.1.5 Others
  • 7.2 By Application
    • 7.2.1 Diagnostic Centers/Clinics
    • 7.2.2 Hospital
    • 7.2.3 Home Setting
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 US
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 Germany
      • 7.3.2.2 UK
      • 7.3.2.3 France
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive landscape

  • 8.1 Mergers and Acquisition Analysis
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 F. Hoffmann-La Roche
  • 9.2 Lifescan
  • 9.3 Bayer Healthcare Ag
  • 9.4 Abbott Laboratories
  • 9.5 Arkay Inc.
  • 9.6 Roche Diagnostic
  • 9.7 Others

10. Future of the Market

Back to Top